{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:08:06Z","timestamp":1789877286552,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,1,21]],"date-time":"2017-01-21T00:00:00Z","timestamp":1484956800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"University of British Columbia Clinical Investigator Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s40265-017-0690-8","type":"journal-article","created":{"date-parts":[[2017,1,21]],"date-time":"2017-01-21T07:41:25Z","timestamp":1484984485000},"page":"237-245","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":121,"title":["Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies"],"prefix":"10.1007","volume":"77","author":[{"given":"Kevin A.","family":"Hay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron J.","family":"Turtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,21]]},"reference":[{"key":"690_CR1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","volume":"75","author":"MM Horowitz","year":"1990","unstructured":"Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringd\u00e9n O, Rozman C, Speck B. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555\u201362.","journal-title":"Blood"},{"key":"690_CR2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12185-013-1490-x","volume":"99","author":"CJ Turtle","year":"2014","unstructured":"Turtle CJ. Chimeric antigen receptor modified T cell therapy for B cell malignancies. Int J Hematol. 2014;99:132\u201340.","journal-title":"Int J Hematol"},{"key":"690_CR3","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","volume":"112","author":"BG Till","year":"2008","unstructured":"Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112:2261\u201371.","journal-title":"Blood"},{"key":"690_CR4","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121:1822\u20136.","journal-title":"J Clin Invest"},{"key":"690_CR5","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","volume":"16","author":"MC Jensen","year":"2010","unstructured":"Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, Forman SJ. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transpl. 2010;16:1245\u201356.","journal-title":"Biol Blood Marrow Transpl"},{"key":"690_CR6","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett DM, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509\u201318.","journal-title":"N Engl J Med"},{"key":"690_CR7","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317.","journal-title":"N Engl J Med"},{"key":"690_CR8","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter DL, Hwang W-T, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7:303ra139.","journal-title":"Sci Transl Med"},{"key":"690_CR9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517\u201328.","journal-title":"Lancet"},{"key":"690_CR10","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119:2709\u201320.","journal-title":"Blood"},{"key":"690_CR11","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","volume":"8","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi L-A, Berger C, et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8:355ra116.","journal-title":"Sci Transl Med"},{"key":"690_CR12","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi L-A, Berger C, et al. CD19 CAR-T cells of defined CD4\u00a0+\u00a0:CD8\u00a0+\u00a0composition in adult B cell ALL patients. J Clin Invest. 2016;126:2123\u201338.","journal-title":"J Clin Invest"},{"key":"690_CR13","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","volume":"119","author":"BG Till","year":"2012","unstructured":"Till BG, Jensen MC, Wang J, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 2012;119:3940\u201350.","journal-title":"Blood"},{"key":"690_CR14","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","volume":"15","author":"M Chmielewski","year":"2015","unstructured":"Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15:1145\u201354.","journal-title":"Expert Opin Biol Ther"},{"key":"690_CR15","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1084\/jem.168.3.1205","volume":"168","author":"I Stamenkovic","year":"1988","unstructured":"Stamenkovic I, Seed B. CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail. J Exp Med. 1988;168:1205\u201310.","journal-title":"J Exp Med"},{"key":"690_CR16","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118:4817\u201328.","journal-title":"Blood"},{"key":"690_CR17","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188\u201395.","journal-title":"Blood"},{"key":"690_CR18","doi-asserted-by":"crossref","first-page":"22425","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:22425.","journal-title":"Sci Transl Med"},{"key":"690_CR19","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6:664\u201379.","journal-title":"Cancer Discov"},{"key":"690_CR20","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra38.","journal-title":"Sci Transl Med"},{"key":"690_CR21","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1200\/JCO.2016.34.15_suppl.7003","volume":"34","author":"JH Park","year":"2016","unstructured":"Park JH, Riviere I, Wang X, Purdon T, Sadelain M, Brentjens RJ. Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL. J Clin Oncol. 2016;34:7003 (suppl\u2013abstr).","journal-title":"J Clin Oncol"},{"key":"690_CR22","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","volume":"127","author":"JH Park","year":"2016","unstructured":"Park JH, Geyer MB, Brentjens RJ. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood. 2016;127:3312\u201320.","journal-title":"Blood"},{"key":"690_CR23","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jcyt.2016.07.003","volume":"18","author":"MB Geyer","year":"2016","unstructured":"Geyer MB, Brentjens RJ. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells. Cytotherapy. 2016;18:1393\u2013409.","journal-title":"Cytotherapy"},{"key":"690_CR24","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1182\/blood.V126.23.684.684","volume":"126","author":"DW Lee","year":"2015","unstructured":"Lee DW, Stetler-Stevenson M, Yuan CM, et al. Safety and response of incorporating CD19 chimeric antigen receptor T cell therapy in typical salvage regimens for children and young adults with acute lymphoblastic leukemia. Blood. 2015;126:684.","journal-title":"Blood"},{"key":"690_CR25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1182\/blood.V126.23.99.99","volume":"126","author":"JN Brudno","year":"2015","unstructured":"Brudno JN, Somerville R, Shi V, et al. Allogeneic T-cells expressing an anti-CD19 chimeric antigen receptor cause remissions of B-Cell malignancies after allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease. Blood. 2015;126:99.","journal-title":"Blood"},{"key":"690_CR26","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","volume":"34","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Somerville RPT, Shi V, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. Clin Oncol. 2016;34:1112\u201321.","journal-title":"Clin Oncol"},{"key":"690_CR27","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1200\/JCO.2016.34.15_suppl.3011","volume":"34","author":"SL Maude","year":"2016","unstructured":"Maude SL, Teachey DT, Rheingold SR, et al. Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL. J Clin Oncol. 2016;34:3011 (suppl\u2013abstr).","journal-title":"J Clin Oncol"},{"key":"690_CR28","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1200\/JCO.2016.34.15_suppl.7002","volume":"34","author":"NV Frey","year":"2016","unstructured":"Frey NV, Shaw PA, Hexner EO, et al. Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r\/r) acute lymphoblastic leukemia (ALL). J Clin Oncol. 2016;34:7002 (suppl\u2013abstr).","journal-title":"J Clin Oncol"},{"key":"690_CR29","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","volume":"30","author":"D Sommermeyer","year":"2016","unstructured":"Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, Riddell SR. Chimeric antigen receptor-modified T cells derived from defined CD8\u00a0+\u00a0and CD4\u00a0+\u00a0subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30:492\u2013500.","journal-title":"Leukemia"},{"key":"690_CR30","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540\u20139.","journal-title":"J Clin Oncol"},{"key":"690_CR31","doi-asserted-by":"crossref","first-page":"LBA3010","DOI":"10.1200\/JCO.2016.34.15_suppl.LBA3010","volume":"34","author":"J Kochenderfer","year":"2016","unstructured":"Kochenderfer J, Somerville R, Lu T, et al. Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma. J Clin Oncol. 2016;34:LBA3010 (suppl\u2013abstr).","journal-title":"J Clin Oncol"},{"key":"690_CR32","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V126.23.183.183","volume":"126","author":"SJ Schuster","year":"2015","unstructured":"Schuster SJ, Svoboda J, Dwivedy Nasta S, et al. Sustained remissions following chimeric antigen receptor modified t cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. Blood. 2015;126:183.","journal-title":"Blood"},{"key":"690_CR33","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.2016.34.15_suppl.3009","volume":"34","author":"DL Porter","year":"2016","unstructured":"Porter DL, Frey NV, Melenhorst JJ, et al. Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R\/R) CLL. J Clin Oncol. 2016;34:3009 (suppl\u2013abstr).","journal-title":"J Clin Oncol"},{"key":"690_CR34","doi-asserted-by":"crossref","first-page":"7526","DOI":"10.1200\/JCO.2015.62.9337","volume":"34","author":"MB Geyer","year":"2016","unstructured":"Geyer MB, Park JH, Riviere I, Wang X, Purdon T, Sadelain M, Brentjens RJ. Updated results: phase I trial of autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy. J Clin Oncol. 2016;34:7526 (suppl\u2013abstr).","journal-title":"J Clin Oncol"},{"key":"690_CR35","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2016.34.15_suppl.102","volume":"34","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi L-A, Berger C, et al. Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition of CD19 CAR-T cells. J Clin Oncol. 2016;34:102 (suppl\u2013abstr).","journal-title":"J Clin Oncol"},{"key":"690_CR36","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17:1290\u20137.","journal-title":"Nat Med"},{"key":"690_CR37","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","volume":"121","author":"N Cieri","year":"2013","unstructured":"Cieri N, Camisa B, Cocchiarella F, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood. 2013;121:573\u201384.","journal-title":"Blood"},{"key":"690_CR38","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1182\/blood-2007-09-113050","volume":"111","author":"CS Hinrichs","year":"2008","unstructured":"Hinrichs CS, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, Palmer DC, Klebanoff CA, Rosenberg SA, Leonard WJ, Restifo NP. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood. 2008;111:5326\u201333.","journal-title":"Blood"},{"key":"690_CR39","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126:3130\u201344.","journal-title":"J Clin Invest"},{"key":"690_CR40","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/mt.2016.63","volume":"24","author":"T Gargett","year":"2016","unstructured":"Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, Lewis ID, Brenner MK, Brown MP. GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol Ther. 2016;24:1135\u201349.","journal-title":"Mol Ther"},{"key":"690_CR41","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282\u201395.","journal-title":"Cancer Discov"},{"key":"690_CR42","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner R, Wu D, Cherian S, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127:2406\u201310.","journal-title":"Blood"},{"key":"690_CR43","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","volume":"121","author":"W Haso","year":"2013","unstructured":"Haso W, Lee DW, Shah NN, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121:1165\u201374.","journal-title":"Blood"},{"key":"690_CR44","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","volume":"4","author":"E Zah","year":"2016","unstructured":"Zah E, Lin M-Y, Silva-Benedict A, Jensen MC, Chen YY. T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res. 2016;4:498\u2013508.","journal-title":"Cancer Immunol Res"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0690-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0690-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0690-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T09:38:09Z","timestamp":1601372289000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0690-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,21]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["690"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0690-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,21]]}}}